BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?

11.12.24 15:50 Uhr

Werte in diesem Artikel
Aktien

63,86 EUR -0,26 EUR -0,41%

Indizes

20.109,1 PKT -64,8 PKT -0,32%

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.The Style Scores are broken down into four categories:Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.That's where the Style Scores come in.To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: BioMarin Pharmaceutical (BMRN) San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children.BMRN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.Momentum investors should take note of this Medical stock. BMRN has a Momentum Style Score of B, and shares are up 0.5% over the past four weeks.11 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.04 to $3.28 per share. BMRN boasts an average earnings surprise of 28.7%.With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, BMRN should be on investors' short list.Should You Invest in BioMarin Pharmaceutical Inc. (BMRN)?Before you invest in BioMarin Pharmaceutical Inc. (BMRN), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Biomarin Pharmaceutical

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Biomarin Pharmaceutical

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Biomarin Pharmaceutical Inc.

Analysen zu Biomarin Pharmaceutical Inc.

DatumRatingAnalyst
14.12.2018Biomarin Pharmaceutical OutperformWolfe Research
01.10.2018Biomarin Pharmaceutical OverweightCantor Fitzgerald
07.08.2018Biomarin Pharmaceutical BuyStifel, Nicolaus & Co., Inc.
03.08.2018Biomarin Pharmaceutical BuyStifel, Nicolaus & Co., Inc.
16.05.2018Biomarin Pharmaceutical BuyCanaccord Adams
DatumRatingAnalyst
14.12.2018Biomarin Pharmaceutical OutperformWolfe Research
01.10.2018Biomarin Pharmaceutical OverweightCantor Fitzgerald
07.08.2018Biomarin Pharmaceutical BuyStifel, Nicolaus & Co., Inc.
03.08.2018Biomarin Pharmaceutical BuyStifel, Nicolaus & Co., Inc.
16.05.2018Biomarin Pharmaceutical BuyCanaccord Adams
DatumRatingAnalyst
15.09.2017Biomarin Pharmaceutical Sector PerformRBC Capital Markets
30.03.2017Biomarin Pharmaceutical NeutralUBS AG
02.03.2017Biomarin Pharmaceutical NeutralInstinet
29.02.2016Biomarin Pharmaceutical NeutralWedbush Morgan Securities Inc.
25.11.2015Biomarin Pharmaceutical PerformOppenheimer & Co. Inc.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Biomarin Pharmaceutical Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"